[G04] Goat Anti-Human Apolipoprotein CIII Sepharose™ 4B Gel

33A-G1 Resin-1ml

Academy Bio-Medical Company, Inc.

$1,626.00

Host Species:	Goat
Concentration:	≥ 5 mg/ml
Source:	Polyclonal goat antibody human apo CIII coupled with CNBr-activated Sepharose 4B™.
Preservation:	75 mM PBS, 75 mM NaCl, 0.5 mM EDTA, 0.02% NaN3, 0.1mM PMSF, pH 7.3.
Specificity	Specifically binds to human apo CIII.
Use:	Affinity purification column.
Storage:	2-8ºC store in buffer with 0.5 mM EDTA and 0.02% NaN3, 0.1 mM PMSF. DO NOT FREEZE!

*Sepharose is a trademark of GE Healthcare Life Sciences, Sweden.

** These products are for research or manufacturing use only, not for use in human therapeutic or diagnostic applications.

Importance

Apo CIII contains 79 amino acid residues. The m.w. is 8.7 kDa (Brewer et al., 1974).

It may inhibit the activation of lipoprotein lipase by apo CIII. Apo CIII is a constituent of both apoB- and apoAI-containing lipoproteins in the circulation. Apo CIII plays a pivotal role in regulating the plasma metabolism of VLDL, IDL, and LDL, primarily by inhibiting receptor-mediated uptake of these lipoproteins by the liver (Sehayek and Eisenberg 1991, Aalto-Setala et al., 1992, Zheng et al., 2007)

Brewer, H. B., R. Shulman, P. Herbert, R. Ronan, and K. Wehrly. “The complete amino acid sequence of alanine apolipoprotein (apoC-3), and apolipoprotein from human plasma very low density lipoproteins.” J Biol Chem 249.15 (1974):4975-84.

Sehayek , E. , and S. Eisenberg . “Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.” J. Biol. Chem. 266 (1991) : 18259 – 18267 .

Aalto-Setala , K., E. A. Fisher , X. Chen , T. Chajek-Shaul , T. Hayek , R. Zechner , A. Walsh , R. Ramakrishnan , H. N. Ginsberg , and J. L. Breslow . “ Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.” J. Clin. Invest. 90 (1992): 1889 – 1900.

Zheng , C. , C. Khoo , K. Ikewaki , and F. M. Sacks . “ Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions.” J. Lipid Res. 48 (2007): 1190 -203.

Citations

[G04]	2017	Koch, Manja; Furtado, Jeremy D.; Jiang, Gordon Z.; Gray, Brianna E.; Cai, Tianxi; Sacks, Frank et al. (2017): Associations of anthropometry and lifestyle factors with HDL subspecies according to apolipoprotein C-III. In Journal of Lipid Research 58 (6), pp. 1196–1203. DOI: 10.1194/jlr.P073288.
[G04]	2013	Mendivil, Carlos O.; Rimm, Eric B.; Furtado, Jeremy; Sacks, Frank M. (2013): Apolipoprotein E in VLDL and LDL With Apolipoprotein C‐III is Associated With a Lower Risk of Coronary Heart Disease. In Journal of the American Heart Association 2 (3), p. 1239. DOI: 10.1161/JAHA.113.000130.
[G04]	2012	Jensen, Majken K.; Rimm, Eric B.; Furtado, Jeremy D.; Sacks, Frank M. (2012): Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. In Journal of the American Heart Association 1 (2). DOI: 10.1161/JAHA.111.000232.
[G04]	2010	Furtado, Jeremy D.; Campos, Hannia; Sumner, Anne E.; Appel, Lawrence J.; Carey, Vincent J.; Sacks, Frank M. (2010): Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial. In The American Journal of Clinical Nutrition 92 (4), pp. 714–722. DOI: 10.3945/ajcn.2009.28532.
[G04]	2010	Zheng, Chunyu; Khoo, Christina; Furtado, Jeremy; Sacks, Frank M. (2010): Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein Phenotype. In Circulation 121 (15), pp. 1722–1734. DOI: 10.1161/CIRCULATIONAHA.109.875807.
[G04]	2008	Furtado, Jeremy D.; Campos, Hannia; Appel, Lawrence J.; Miller, Edgar R.; Laranjo, Nancy; Carey, Vincent J.; Sacks, Frank M. (2008): Effect of protein, unsaturated fat, and carbohydrate intakes on plasma apolipoprotein B and VLDL and LDL containing apolipoprotein C-III: results from the OmniHeart Trial. In The American Journal of Clinical Nutrition 87 (6), pp. 1623–1630. DOI: 10.1093/ajcn/87.6.1623.
[G04]	2007	Zheng, Chunyu; Khoo, Christina; Ikewaki, Katsunori; Sacks, Frank M. (2007): Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. In J. Lipid Res. 48 (5), pp. 1190–1203. DOI: 10.1194/jlr.P600011-JLR200.

We Also Recommend

[A01] Goat Anti-Human Albumin Polyclonal Antibody

[A02] Sheep Anti-Human Apolipoprotein (a) Polyclonal Antibody

[A03R] Rabbit Anti-Human Apolipoprotein AI Polyclonal Antibody

[A03] Goat Anti-Human Apolipoprotein AI Polyclonal Antibody

[A04] Goat Anti-Human Apolipoprotein AII Polyclonal Antibody